BRIEF-Eisai And Biogen Announce U.S. Availability Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection Maintenance Dose For Treatment Of Early Alzheimer’S Disease

Oct 6 (Reuters) – * EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)